Pirfenidone in Patients with Unclassifiable Interstitial Lung Disease

Pirfenidone in patients with unclassifiable progressive fibrosing ...

Pirfenidone is an antifibrotic shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF), a form of ILD that has ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung ...

Approximately 12–13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough ...

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung ...

These results suggest that SLB status does not substantially impact this treatment benefit; however, further studies in larger patient ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

Pirfenidone is an antifibrotic shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF), a form of ILD that has mechanistic and ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

At present, no approved pharmacotherapies are available for unclassifiable interstitial lung disease (ILD), which is characterised by ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

Introduction Despite extensive multidisciplinary team (MDT) assessment, some patients have interstitial lung disease (ILD) that is considered ...

Safety, tolerability, and efficacy of pirfenidone in patients with ...

On the basis of phase 3 trials, pirfenidone has been approved in many countries for the treatment of patients with idiopathic pulmonary fibrosis.9 We aimed to ...

Phase II trial of pirfenidone in patients with progressive fibrosing ...

Introduction: There are no approved therapies for patients with uILD, who may have irreversible ILD. · Methods: This was a double-blind, randomised, placebo- ...

Pirfenidone in Patients with Unclassifiable Progressive Fibrosing ...

A42. ILD SCIENTIFIC ABSTRACTS: TREATMENT AND ACUTE EXACERBATION · Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: ...

Pirfenidone in Unclassifiable Interstitial Lung Disease - SpringerLink

There are currently no approved treatments solely for unclassifiable interstitial lung disease (uILD); however, a recent trial showed this ...

Phase II Trial of Pirfenidone in Patients With Progressive Fibrosing ...

2016;3:e000105. Phase II Trial of Pirfenidone in Patients With Progressive Fibrosing Unclassifiable ILD (uILD). Toby M. Maher,1 Tamera ...

Press Releases | Monday, Mar 2, 2020 - Genentech

There are currently no FDA-approved treatments for unclassifiable ILD (uILD), a debilitating, severe respiratory condition. The designation is ...

Pirfenidone in patients with unclassifiable progressive fibrosing ...

The term interstitial lung disease (ILD) includes an enormous amount of parenchymal pulmonary disorders (>200). The appropriate and strict ...

Phase 2 Pirfenidone Trial Indicates Potential Effectiveness in ...

Pirfenidone, sold as Esbriet, was shown to potentially benefit patients with progressive fibrosing unclassifiable interstitial lung disease ...

Pirfenidone in Progressive Pulmonary Fibrosis - ATS Journals

Conclusions: Pirfenidone use in patients with PPF is associated with a statistically significant decrease in disease progression and with ...

Press Releases | Wednesday, Jan 20, 2021 - Genentech

FDA Grants Priority Review to Genentech's Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease · have other medical conditions ( ...

Pirfenidone Gets Priority Review for Unclassifiable Interstitial Lung ...

The FDA has granted Priority Review to pirfenidone (Esbriet; Genentech) for the treatment of unclassifiable interstitial lung disease ...

Interstitial Lung disease – Safety and Eff... - Genentech Clinical Trials

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease · Royal Prince Alfred Hospital · John Hunter Hospital; ...

Pirfenidone in Patients with Unclassifiable Interstitial Lung Disease

Watch coverage from the CHEST 2019 Annual Meeting for information regarding Pirfenidone in patients with unclassifiable interstitial lung disease.